Floatz logo

17.BETA.-(1-KETOETHYL)-.DELTA. SUP(5)-ANDROSTEN-3.BETA.-OL

Schizoaffective Disorder Bipolar Type

Sherwood Brown, MD, PhDSmall moleculePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Schizoaffective Disorder Bipolar Type cohort.

Asset / SponsorPhaseRating
CYCLOHEXANEACETIC ACID, 1-(AMINOMETHYL)-
Medical University of South Carolina
Phase 2CCC

Same molecule, other indications

17.BETA.-(1-KETOETHYL)-.DELTA. SUP(5)-ANDROSTEN-3.BETA.-OL is also rated in:

major depressive disorderDormant
BBB
Indicative ·
72 / 100
View asset →
substance abuseDormant
BB
Indicative ·
69 / 100
View asset →
bipolar disorderDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →